Clonal Deletion of Tumor-Specific T Cells by Interferon-γ Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade

Chien Chun Steven Pai, John T. Huang, Xiaoqing Lu, Donald M. Simons, Chanhyuk Park, Anthony Chang, Whitney Tamaki, Eric Liu, Kole T. Roybal, Jane Seagal, Mingyi Chen, Katsunobu Hagihara, Xiao X. Wei, Michel DuPage, Serena S. Kwek, David Y. Oh, Adil Daud, Katy K. Tsai, Clint Wu, Li ZhangMarcella Fasso, Ravi Sachidanandam, Anitha Jayaprakash, Ingrid Lin, Amy Jo Casbon, Gillian A. Kinsbury, Lawrence Fong

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Resistance to checkpoint-blockade treatments is a challenge in the clinic. We found that although treatment with combined anti-CTLA-4 and anti-PD-1 improved control of established tumors, this combination compromised anti-tumor immunity in the low tumor burden (LTB) state in pre-clinical models as well as in melanoma patients. Activated tumor-specific T cells expressed higher amounts of interferon-γ (IFN-γ) receptor and were more susceptible to apoptosis than naive T cells. Combination treatment induced deletion of tumor-specific T cells and altered the T cell repertoire landscape, skewing the distribution of T cells toward lower-frequency clonotypes. Additionally, combination therapy induced higher IFN-γ production in the LTB state than in the high tumor burden (HTB) state on a per-cell basis, reflecting a less exhausted immune status in the LTB state. Thus, elevated IFN-γ secretion in the LTB state contributes to the development of an immune-intrinsic mechanism of resistance to combination checkpoint blockade, highlighting the importance of achieving the optimal magnitude of immune stimulation for successful combination immunotherapy strategies. Although immune checkpoint blockades are being combined to enhance anti-tumor efficacy, Pai et al. find that this approach can lead to therapy resistance in the low tumor burden setting. Potent immunotherapy in this setting overdrives tumor-reactive T cells, leading to their death. Optimal immunotherapy could therefore be disease-context dependent.

Original languageEnglish (US)
Pages (from-to)477-492.e8
JournalImmunity
Volume50
Issue number2
DOIs
StatePublished - Feb 19 2019

Fingerprint

Clonal Deletion
Tumor Burden
Interferons
T-Lymphocytes
Immunotherapy
Neoplasms
Therapeutics
Interferon Receptors
Immunity
Melanoma
Apoptosis

Keywords

  • activation-induced cell death
  • anti-CTLA-4
  • anti-PD-1
  • cancer
  • IFN-γ
  • immunotherapy

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases

Cite this

Clonal Deletion of Tumor-Specific T Cells by Interferon-γ Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade. / Pai, Chien Chun Steven; Huang, John T.; Lu, Xiaoqing; Simons, Donald M.; Park, Chanhyuk; Chang, Anthony; Tamaki, Whitney; Liu, Eric; Roybal, Kole T.; Seagal, Jane; Chen, Mingyi; Hagihara, Katsunobu; Wei, Xiao X.; DuPage, Michel; Kwek, Serena S.; Oh, David Y.; Daud, Adil; Tsai, Katy K.; Wu, Clint; Zhang, Li; Fasso, Marcella; Sachidanandam, Ravi; Jayaprakash, Anitha; Lin, Ingrid; Casbon, Amy Jo; Kinsbury, Gillian A.; Fong, Lawrence.

In: Immunity, Vol. 50, No. 2, 19.02.2019, p. 477-492.e8.

Research output: Contribution to journalArticle

Pai, CCS, Huang, JT, Lu, X, Simons, DM, Park, C, Chang, A, Tamaki, W, Liu, E, Roybal, KT, Seagal, J, Chen, M, Hagihara, K, Wei, XX, DuPage, M, Kwek, SS, Oh, DY, Daud, A, Tsai, KK, Wu, C, Zhang, L, Fasso, M, Sachidanandam, R, Jayaprakash, A, Lin, I, Casbon, AJ, Kinsbury, GA & Fong, L 2019, 'Clonal Deletion of Tumor-Specific T Cells by Interferon-γ Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade', Immunity, vol. 50, no. 2, pp. 477-492.e8. https://doi.org/10.1016/j.immuni.2019.01.006
Pai, Chien Chun Steven ; Huang, John T. ; Lu, Xiaoqing ; Simons, Donald M. ; Park, Chanhyuk ; Chang, Anthony ; Tamaki, Whitney ; Liu, Eric ; Roybal, Kole T. ; Seagal, Jane ; Chen, Mingyi ; Hagihara, Katsunobu ; Wei, Xiao X. ; DuPage, Michel ; Kwek, Serena S. ; Oh, David Y. ; Daud, Adil ; Tsai, Katy K. ; Wu, Clint ; Zhang, Li ; Fasso, Marcella ; Sachidanandam, Ravi ; Jayaprakash, Anitha ; Lin, Ingrid ; Casbon, Amy Jo ; Kinsbury, Gillian A. ; Fong, Lawrence. / Clonal Deletion of Tumor-Specific T Cells by Interferon-γ Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade. In: Immunity. 2019 ; Vol. 50, No. 2. pp. 477-492.e8.
@article{c6020e9c3b244321a389073be0d360cb,
title = "Clonal Deletion of Tumor-Specific T Cells by Interferon-γ Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade",
abstract = "Resistance to checkpoint-blockade treatments is a challenge in the clinic. We found that although treatment with combined anti-CTLA-4 and anti-PD-1 improved control of established tumors, this combination compromised anti-tumor immunity in the low tumor burden (LTB) state in pre-clinical models as well as in melanoma patients. Activated tumor-specific T cells expressed higher amounts of interferon-γ (IFN-γ) receptor and were more susceptible to apoptosis than naive T cells. Combination treatment induced deletion of tumor-specific T cells and altered the T cell repertoire landscape, skewing the distribution of T cells toward lower-frequency clonotypes. Additionally, combination therapy induced higher IFN-γ production in the LTB state than in the high tumor burden (HTB) state on a per-cell basis, reflecting a less exhausted immune status in the LTB state. Thus, elevated IFN-γ secretion in the LTB state contributes to the development of an immune-intrinsic mechanism of resistance to combination checkpoint blockade, highlighting the importance of achieving the optimal magnitude of immune stimulation for successful combination immunotherapy strategies. Although immune checkpoint blockades are being combined to enhance anti-tumor efficacy, Pai et al. find that this approach can lead to therapy resistance in the low tumor burden setting. Potent immunotherapy in this setting overdrives tumor-reactive T cells, leading to their death. Optimal immunotherapy could therefore be disease-context dependent.",
keywords = "activation-induced cell death, anti-CTLA-4, anti-PD-1, cancer, IFN-γ, immunotherapy",
author = "Pai, {Chien Chun Steven} and Huang, {John T.} and Xiaoqing Lu and Simons, {Donald M.} and Chanhyuk Park and Anthony Chang and Whitney Tamaki and Eric Liu and Roybal, {Kole T.} and Jane Seagal and Mingyi Chen and Katsunobu Hagihara and Wei, {Xiao X.} and Michel DuPage and Kwek, {Serena S.} and Oh, {David Y.} and Adil Daud and Tsai, {Katy K.} and Clint Wu and Li Zhang and Marcella Fasso and Ravi Sachidanandam and Anitha Jayaprakash and Ingrid Lin and Casbon, {Amy Jo} and Kinsbury, {Gillian A.} and Lawrence Fong",
year = "2019",
month = "2",
day = "19",
doi = "10.1016/j.immuni.2019.01.006",
language = "English (US)",
volume = "50",
pages = "477--492.e8",
journal = "Immunity",
issn = "1074-7613",
publisher = "Cell Press",
number = "2",

}

TY - JOUR

T1 - Clonal Deletion of Tumor-Specific T Cells by Interferon-γ Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade

AU - Pai, Chien Chun Steven

AU - Huang, John T.

AU - Lu, Xiaoqing

AU - Simons, Donald M.

AU - Park, Chanhyuk

AU - Chang, Anthony

AU - Tamaki, Whitney

AU - Liu, Eric

AU - Roybal, Kole T.

AU - Seagal, Jane

AU - Chen, Mingyi

AU - Hagihara, Katsunobu

AU - Wei, Xiao X.

AU - DuPage, Michel

AU - Kwek, Serena S.

AU - Oh, David Y.

AU - Daud, Adil

AU - Tsai, Katy K.

AU - Wu, Clint

AU - Zhang, Li

AU - Fasso, Marcella

AU - Sachidanandam, Ravi

AU - Jayaprakash, Anitha

AU - Lin, Ingrid

AU - Casbon, Amy Jo

AU - Kinsbury, Gillian A.

AU - Fong, Lawrence

PY - 2019/2/19

Y1 - 2019/2/19

N2 - Resistance to checkpoint-blockade treatments is a challenge in the clinic. We found that although treatment with combined anti-CTLA-4 and anti-PD-1 improved control of established tumors, this combination compromised anti-tumor immunity in the low tumor burden (LTB) state in pre-clinical models as well as in melanoma patients. Activated tumor-specific T cells expressed higher amounts of interferon-γ (IFN-γ) receptor and were more susceptible to apoptosis than naive T cells. Combination treatment induced deletion of tumor-specific T cells and altered the T cell repertoire landscape, skewing the distribution of T cells toward lower-frequency clonotypes. Additionally, combination therapy induced higher IFN-γ production in the LTB state than in the high tumor burden (HTB) state on a per-cell basis, reflecting a less exhausted immune status in the LTB state. Thus, elevated IFN-γ secretion in the LTB state contributes to the development of an immune-intrinsic mechanism of resistance to combination checkpoint blockade, highlighting the importance of achieving the optimal magnitude of immune stimulation for successful combination immunotherapy strategies. Although immune checkpoint blockades are being combined to enhance anti-tumor efficacy, Pai et al. find that this approach can lead to therapy resistance in the low tumor burden setting. Potent immunotherapy in this setting overdrives tumor-reactive T cells, leading to their death. Optimal immunotherapy could therefore be disease-context dependent.

AB - Resistance to checkpoint-blockade treatments is a challenge in the clinic. We found that although treatment with combined anti-CTLA-4 and anti-PD-1 improved control of established tumors, this combination compromised anti-tumor immunity in the low tumor burden (LTB) state in pre-clinical models as well as in melanoma patients. Activated tumor-specific T cells expressed higher amounts of interferon-γ (IFN-γ) receptor and were more susceptible to apoptosis than naive T cells. Combination treatment induced deletion of tumor-specific T cells and altered the T cell repertoire landscape, skewing the distribution of T cells toward lower-frequency clonotypes. Additionally, combination therapy induced higher IFN-γ production in the LTB state than in the high tumor burden (HTB) state on a per-cell basis, reflecting a less exhausted immune status in the LTB state. Thus, elevated IFN-γ secretion in the LTB state contributes to the development of an immune-intrinsic mechanism of resistance to combination checkpoint blockade, highlighting the importance of achieving the optimal magnitude of immune stimulation for successful combination immunotherapy strategies. Although immune checkpoint blockades are being combined to enhance anti-tumor efficacy, Pai et al. find that this approach can lead to therapy resistance in the low tumor burden setting. Potent immunotherapy in this setting overdrives tumor-reactive T cells, leading to their death. Optimal immunotherapy could therefore be disease-context dependent.

KW - activation-induced cell death

KW - anti-CTLA-4

KW - anti-PD-1

KW - cancer

KW - IFN-γ

KW - immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=85061089067&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061089067&partnerID=8YFLogxK

U2 - 10.1016/j.immuni.2019.01.006

DO - 10.1016/j.immuni.2019.01.006

M3 - Article

C2 - 30737146

AN - SCOPUS:85061089067

VL - 50

SP - 477-492.e8

JO - Immunity

JF - Immunity

SN - 1074-7613

IS - 2

ER -